

Erratum

First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia: Am J Cancer Res. 2018; 8(6): 1083-1089

Xiaowen Tang^{1,2,3*}, Lin Yang^{3,4,5*}, Zheng Li^{1,2,3}, Ansel P Nalin⁶, Haiping Dai^{1,2,3}, Ting Xu^{1,2,3}, Jia Yin^{1,2,3}, Fengtao You^{3,4,5}, Mingqing Zhu^{1,2,3}, Wenhong Shen^{1,2,3}, Guanghua Chen^{1,2,3}, Xiaming Zhu^{1,2,3}, Depei Wu^{1,2,3}, Jianhua Yu^{6,7,8}

¹The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Suzhou, China; ²Institute of Blood and Bone Marrow Transplantation, Suzhou, China; ³Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China; ⁴The Cyrus Tang Hematology Center, Soochow University, Suzhou, China; ⁵Persongen Biotherapeutics Co., Ltd., Suzhou, China; ⁶Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA; ⁷The James Cancer Hospital, The Ohio State University, Columbus, OH 43210, USA; ⁸Division of Hematology, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH 43210, USA. *Equal contributors.

Received August 10, 2018; Accepted August 13, 2018; Epub September 1, 2018; Published September 15, 2018

In the paper above entitled, “First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia” by Tang et al., published in *Am J Cancer Res* (2018;8(6):1083-1089), the authors would like to change the first affiliation from “Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China” to “The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Suzhou, China”. We also would like to add this corrected affiliation to the first author’s affiliation list. The correct author and affiliation information on the first page of the article should read as follows:

Xiaowen Tang^{1,2,3*}, Lin Yang^{3,4,5*}, Zheng Li^{1,2,3}, Ansel P Nalin⁶, Haiping Dai^{1,2,3}, Ting Xu^{1,2,3}, Jia Yin^{1,2,3}, Fengtao You^{3,4,5}, Mingqing Zhu^{1,2,3}, Wenhong Shen^{1,2,3}, Guanghua Chen^{1,2,3}, Xiaming Zhu^{1,2,3}, Depei Wu^{1,2,3}, Jianhua Yu^{6,7,8}

¹The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Suzhou, China; ²Institute of Blood and Bone Marrow Transplantation, Suzhou, China; ³Colla-

borative Innovation Center of Hematology, Soochow University, Suzhou, China; ⁴The Cyrus Tang Hematology Center, Soochow University, Suzhou, China; ⁵Persongen BioTherapeutics Co., Ltd., Suzhou, China; ⁶Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA; ⁷The James Cancer Hospital, The Ohio State University, Columbus, OH 43210, USA; ⁸Division of Hematology, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH 43210, USA. *Equal contributors.

Address correspondence to: Xiaowen Tang, Department of Hematology, The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Suzhou, China. E-mail: tangxiaowen@suda.edu.cn; Depei Wu, Department of Hematology, The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Suzhou, China. E-mail: drwudepei@163.com; Jianhua Yu, The Ohio State University, Biomedical Research Tower 816, 460 West 12th Avenue, Columbus, OH 43210. E-mail: jianhua.yu@osumc.edu